Translation of nanoparticles (NPs) into human clinical trials for patients with refractory
cancers has lagged due to unknown biologic reactivities of novel NP designs. To overcome …

Harnessing mRNA–lipid nanoparticles (LNPs) to treat patients with cancer has been an
ongoing research area that started before these versatile nanoparticles were successfully …

While RNA-pulsed dendritic cell (DC) vaccines have shown promise, the advancement of
cellular therapeutics is fraught with developmental challenges. To circumvent the challenges …

Effective cancer immunotherapy is usually blocked by immunosuppressive factors in the
tumour microenvironment, resulting in tumour promotion, metastasis and recurrence. Here …

Lipid nanoparticles (LNPs) can be designed to potentiate cancer immunotherapy by
promoting their uptake by antigen-presenting cells, stimulating the maturation of these cells …

Messenger RNA (mRNA) vaccines constitute an emerging therapeutic method with the
advantages of high safety and efficiency as well as easy synthesis; thus, they have been …

Immunotherapy is revolutionizing the clinical management of patients with different cancer
types by sensitizing autologous or allogenic immune cells to the tumor microenvironment …

Decades of oncologic clinical use have demonstrated that cancer immunotherapy provides
unprecedented therapeutic benefits. Tragically, only a minority of patients respond to …

Cancer immunotherapy, which harnesses the power of the immune system, has shown
immense promise in the fight against malignancies. Messenger RNA (mRNA) stands as a …

Purpose Hepatocellular carcinoma (HCC) is one of the leading causes of cancer-related
deaths worldwide. Most current therapeutic strategies primarily include localized treatment …